Top

Current Atherosclerosis Reports

Published in:

01-12-2017 | Nonstatin Drugs (E. deGoma, Section Editor)

ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen

Authors: Natalia A. Rocha, Cara East, Jun Zhang, Peter A. McCullough

Published in: Current Atherosclerosis Reports | Issue 12/2017

Abstract

Purpose of Review

Apolipoprotein CIII (ApoCIII) is now recognized as a key regulator in severe hypertriglyceridemia, chylomicronemia, and conditions of triglyceride-rich lipoprotein (TRL) remnant excess due to its inhibition of lipoprotein lipase (LPL) and hepatic lipase, leading to decreased hepatic reuptake of TRLs, as well as enhanced synthesis and secretion of VLDL from the liver. ApoCIII gain-of-function mutations are associated with atherosclerosis and coronary heart disease (CHD), and contribute to the development of cardiometabolic syndrome, hypertriglyceridemia, and type 2 diabetes mellitus. Conversely, loss-of-function mutations in ApoCIII are associated with lower levels of plasma triglycerides (TG), attenuation of vascular inflammatory processes such as monocyte adhesion and endothelial dysfunction, and potentially, a reduction in the incidence and progression of atherosclerosis and cardioprotection.

Recent Findings

Evidence is now emerging that volanesorsen, a second-generation antisense oligonucleotide drug targeting ApoCIII messenger RNA resulting in decreases in TG in patients with familial chylomicronemia syndrome, severe hypertriglyceridemia, and metabolic dyslipidemia with type 2 diabetes giving support to the hypothesis that ApoCIII is a powerful inhibitor of LPL, and when reduced, endogenous clearance of TRLs can result in substantial reductions in TG levels.

Summary

Discovery of the ApoCIII inhibitor volanesorsen opens a new era of lipid-lowering drugs for reduction in TG and potentially for reduction in LDL-C. Herein, this review will provide an update on the pathophysiology of ApoCIII-linked atherosclerosis and the development of the first drug to target ApoCIII, volanesorsen, as a promising lipid-lowering agent.

Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000. https://doi.org/10.1001/jama.2009.1619.CrossRefPubMed

Reiner Z. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol. 2013;10(8):453–64. https://doi.org/10.1038/nrcardio.2013.80.CrossRefPubMed

Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003;2(7):517–26. https://doi.org/10.1038/nrd1112. CrossRefPubMed

Steinberg D, Gotto AM Jr. Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. JAMA. 1999;282(21):2043–50.CrossRefPubMed

Keys A, Menotti A, Aravanis C, Blackburn H, Djordevic BS, Buzina R, et al. The seven countries study: 2,289 deaths in 15 years. Prev Med. 1984;13(2):141–54.CrossRefPubMed

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (London, England). 1994;344(8934):1383–9

Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1996;156(18):2085–92.CrossRefPubMed

Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–7. https://doi.org/10.1056/nejm199511163332001. CrossRefPubMed

Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (London, England). 2003;361(9364):1149–58. https://doi.org/10.1016/s0140-6736(03)12948-0.CrossRef

10.

• Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22. https://doi.org/10.1056/NEJMoa1615664. First cardiovascular outcomes trial with one of the new cholesterol-lowering PCSK9 inhibitors. CrossRefPubMed

11.

Superko HR, King S 3rd. Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation. 2008;117(4):560–568; discussion 8. https://doi.org/10.1161/circulationaha.106.667428.CrossRefPubMed

12.

Reiner Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr Metabolism Cardiovasc Dis: NMCD. 2013;23(9):799–807. https://doi.org/10.1016/j.numecd.2013.05.002. CrossRefPubMed

13.

Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67. https://doi.org/10.1056/NEJMoa1107579. CrossRefPubMed

14.

Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (London, England). 2012;380(9841):572–80. https://doi.org/10.1016/s0140-6736(12)60312-2.CrossRef

15.

• Pechlaner R, Tsimikas S, Yin X, Willeit P, Baig F, Santer P, et al. Very-low-density lipoprotein-associated apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-III. J Am Coll Cardiol. 2017;69(7):789–800. https://doi.org/10.1016/j.jacc.2016.11.065. Prospective, population-based study showing strong associations of VLDL-associated apolipoproteins with incident CVD in the general community. CrossRefPubMedPubMedCentral

16.

Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N Engl J Med. 1980;302(25):1383–9. https://doi.org/10.1056/nejm198006193022503. CrossRefPubMed

17.

NIH Consensus conference. Triglyceride, high-density lipoprotein, and coronary heart disease. NIH consensus development panel on triglyceride, high-density lipoprotein, and coronary heart disease. JAMA. 1993;269(4):505–10.CrossRef

18.

Carroll MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon DJ, Wolz M, et al. Trends in serum lipids and lipoproteins of adults, 1960–2002. JAMA. 2005;294(14):1773–81. https://doi.org/10.1001/jama.294.14.1773.CrossRefPubMed

19.

Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123(20):2292–333. https://doi.org/10.1161/CIR.0b013e3182160726.CrossRefPubMed

20.

Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299–308. https://doi.org/10.1001/jama.298.3.299.CrossRefPubMed

21.

Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (London, England: 1979). 2008;114(10):611–24. https://doi.org/10.1042/cs20070308. CrossRef

22.

• Reiner Z. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol. 2017; https://doi.org/10.1038/nrcardio.2017.31. Thorough review of hypertriglyceridemia and coronary artery disease with good figures.

23.

Kugiyama K, Doi H, Motoyama T, Soejima H, Misumi K, Kawano H, et al. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation. 1998;97(25):2519–26.CrossRefPubMed

24.

Ginsberg HN, Brown WV. Apolipoprotein CIII: 42 years old and even more interesting. Arterioscler Thromb Vasc Biol. 2011;31(3):471–3. https://doi.org/10.1161/atvbaha.110.221846.CrossRefPubMed

25.

• Norata GD, Tsimikas S, Pirillo A, Catapano AL. Apolipoprotein C-III: from pathophysiology to pharmacology. Trends Pharmacol Sci. 2015;36(10):675–87. https://doi.org/10.1016/j.tips.2015.07.001. Thorough review on Apolipoprotein C III with good figures. CrossRefPubMed

26.

Kohan AB. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2015;22(2):119–25. https://doi.org/10.1097/med.0000000000000136.CrossRefPubMedPubMedCentral

27.

• Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22–31. https://doi.org/10.1056/NEJMoa1307095. Interesting exome analysis of genes associated with plasma triglyceride levels followed by an evaluation of the association between these genes and risk of coronary heart disease. CrossRefPubMed

28.

• Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32–41. https://doi.org/10.1056/NEJMoa1308027.. Population study showing an association between loss-of-function mutations in APOC3 and risks of ischemic vascular disease and ischemic heart disease. CrossRefPubMed

29.

Luo M, Peng D. The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism. Lipids Health Dis. 2016;15(1):184. https://doi.org/10.1186/s12944-016-0352-y. CrossRefPubMedPubMedCentral

30.

Tachmazidou I, Dedoussis G, Southam L, Farmaki AE, Ritchie GR, Xifara DK, et al. A rare functional cardioprotective APOC3 variant has risen in frequency in distinct population isolates. Nat Commun. 2013;4:2872. https://doi.org/10.1038/ncomms3872.CrossRefPubMedPubMedCentral

31.

Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science (New York, NY). 2008;322(5908):1702–5. https://doi.org/10.1126/science.1161524. CrossRef

32.

Wang F, Kohan AB, Dong HH, Yang Q, Xu M, Huesman S, et al. Overexpression of apolipoprotein C-III decreases secretion of dietary triglyceride into lymph. Physiol Rep. 2014;2(3):e00247. https://doi.org/10.1002/phy2.247. CrossRefPubMedPubMedCentral

33.

Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345–61. https://doi.org/10.1093/eurheartj/ehr112.CrossRefPubMedPubMedCentral

34.

Wang YI, Bettaieb A, Sun C, DeVerse JS, Radecke CE, Mathew S, et al. Triglyceride-rich lipoprotein modulates endothelial vascular cell adhesion molecule (VCAM)-1 expression via differential regulation of endoplasmic reticulum stress. PLoS One. 2013;8(10):e78322. https://doi.org/10.1371/journal.pone.0078322.CrossRefPubMedPubMedCentral

35.

Wang L, Gill R, Pedersen TL, Higgins LJ, Newman JW, Rutledge JC. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J Lipid Res. 2009;50(2):204–13. https://doi.org/10.1194/jlr.M700505-JLR200.CrossRefPubMedPubMedCentral

36.

Eiselein L, Wilson DW, Lame MW, Rutledge JC. Lipolysis products from triglyceride-rich lipoproteins increase endothelial permeability, perturb zonula occludens-1 and F-actin, and induce apoptosis. Am J Physiol Heart Circ Physiol. 2007;292(6):H2745–53. https://doi.org/10.1152/ajpheart.00686.2006.CrossRefPubMed

37.

Kawakami A, Yoshida M. Apolipoprotein CIII links dyslipidemia with atherosclerosis. J Atheroscler Thromb. 2009;16(1):6–11.CrossRefPubMed

38.

Li H, Han Y, Qi R, Wang Y, Zhang X, Yu M, et al. Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII. Cardiovasc Res. 2015;107(4):579–89. https://doi.org/10.1093/cvr/cvv192.CrossRefPubMed

39.

Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation. 2006;114(7):681–7. https://doi.org/10.1161/circulationaha.106.622514.CrossRefPubMed

40.

Kawakami A, Aikawa M, Nitta N, Yoshida M, Libby P, Sacks FM. Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation. Arterioscler Thromb Vasc Biol. 2007;27(1):219–25. https://doi.org/10.1161/01.ATV.0000249620.68705.0d.CrossRefPubMed

41.

Zheng C, Azcutia V, Aikawa E, Figueiredo JL, Croce K, Sonoki H, et al. Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. Eur Heart J. 2013;34(8):615–24. https://doi.org/10.1093/eurheartj/ehs271.CrossRefPubMed

42.

Talayero B, Wang L, Furtado J, Carey VJ, Bray GA, Sacks FM. Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease. J Lipid Res. 2014;55(10):2167–77. https://doi.org/10.1194/jlr.M042333.CrossRefPubMedPubMedCentral

43.

Xiong X, Liu H, Hua L, Zhao H, Wang D, Li Y. The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it. Lipids Health Dis. 2015;14:127. https://doi.org/10.1186/s12944-015-0129-8.CrossRefPubMedPubMedCentral

44.

Jensen MK, Rimm EB, Furtado JD, Sacks FM. Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease. J Am Heart Assoc. 2012;1(2). https://doi.org/10.1161/jaha.111.000232.

45.

Riwanto M, Rohrer L, Roschitzki B, Besler C, Mocharla P, Mueller M, et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation. 2013;127(8):891–904. https://doi.org/10.1161/circulationaha.112.108753.CrossRefPubMed

46.

• Mendivil CO, Rimm EB, Furtado J, Chiuve SE, Sacks FM. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation. 2011;124(19):2065–72. https://doi.org/10.1161/circulationaha.111.056986. Prospective cohort study of individuals initially free of cardiovascular disease showing a significant higher risk of CHD in patients with LDL that contains APOC-III when compared to LDL that does not contain APOCIII. CrossRefPubMedPubMedCentral

47.

Lee SJ, Campos H, Moye LA, Sacks FM. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol. 2003;23(5):853–8. https://doi.org/10.1161/01.atv.0000066131.01313.eb.CrossRefPubMed

48.

Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J, et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest. 1995;95(2):705–12. https://doi.org/10.1172/jci117717. CrossRefPubMedPubMedCentral

49.

Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. J Clin Lipidol. 2011;5(6):483–92. https://doi.org/10.1016/j.jacl.2011.09.001.CrossRefPubMed

50.

Dallinga-Thie GM, Berk P II, Bootsma AH, Jansen H. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides. Diabetes Care. 2004;27(6):1358–64.CrossRefPubMed

51.

Chan DC, Watts GF, Ooi EM, Ji J, Johnson AG, Barrett PH. Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(10):1831–7. https://doi.org/10.1161/atvbaha.108.170530.CrossRefPubMedPubMedCentral

52.

Ooi EM, Watts GF, Chan DC, Chen MM, Nestel PJ, Sviridov D, et al. Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome. Diabetes Care. 2008;31(8):1656–61. https://doi.org/10.2337/dc08-0358.CrossRefPubMedPubMedCentral

53.

Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bensadoun A, et al. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest. 2005;115(5):1323–32. https://doi.org/10.1172/jci23219. CrossRefPubMedPubMedCentral

54.

• Graham MJ, Lee RG, Bell TA 3rd, Fu W, Mullick AE, Alexander VJ, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112(11):1479–90. https://doi.org/10.1161/circresaha.111.300367.CrossRefPubMed

55.

•• Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373(5):438–47. https://doi.org/10.1056/NEJMoa1400283.. Randomized, double-blind, placebo-controlled, phase 2 study of volanesorsen in patients with hypertriglyceridemia. CrossRefPubMed

56.

• Yang X, Lee SR, Choi YS, Alexander VJ, Digenio A, Yang Q, et al. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. J Lipid Res. 2016;57(4):706–13. https://doi.org/10.1194/jlr.M066399. Study with antisense inhibitor of APOC3 synthesis in patients with the FCS and LPL deficiency suggesting that APOC3 also strongly regulates the metabolism of TRL through LPL-independent pathways. CrossRefPubMedPubMedCentral

57.

•• Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371(23):2200–6. https://doi.org/10.1056/NEJMoa1400284.. Randomized, double blind phase 3 study with volanesorsen in FCS. CrossRefPubMed

58.

• Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, et al. Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care. 2016;39(8):1408–15. https://doi.org/10.2337/dc16-0126. Randomized, double-blind, placebo-controlled trial of volanesorsen in patients with diabetes. CrossRefPubMed

59.

• Stegemann C, Pechlaner R, Willeit P, Langley SR, Mangino M, Mayr U, et al. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation. 2014;129(18):1821–31. https://doi.org/10.1161/circulationaha.113.002500. Study applying mass spectrometry-based lipidomics profiling to the Bruneck study population. CrossRefPubMed

60.

•• Gaudet D, Digenio A, Alexander VJ, Arca M, Jones AF, Stroes E et al. The APPROACH study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). J Clin Lipidol. 2017;11(3):814–5. https://doi.org/10.1016/j.jacl.2017.04.071. Randomized, double blind phase 3 study with volanesorsen in FCS.

61.

Gouni-Berthold I, Alexander V, Digenio A, DuFour R, Steinhagen-Thiessen E, Martin S et al. Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): a randomized, double-blind, placebo-controlled trial. J Clin Lipidol. 2017;11(3):794–5. https://doi.org/10.1016/j.jacl.2017.04.038.

62.

Dewey FE, Gusarova V, O’Dushlaine C, Gottesman O, Trejos J, Hunt C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374(12):1123–33. https://doi.org/10.1056/NEJMoa1510926. CrossRefPubMedPubMedCentral

63.

Stitziel NO, Stirrups KE, Masca NG, Erdmann J, Ferrario PG, Konig IR, et al. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med. 2016;374(12):1134–44. https://doi.org/10.1056/NEJMoa1507652. CrossRefPubMed

64.

Romeo S, Yin W, Kozlitina J, Pennacchio LA, Boerwinkle E, Hobbs HH, et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest. 2009;119(1):70–9. https://doi.org/10.1172/jci37118. PubMed

65.

Helgadottir A, Gretarsdottir S, Thorleifsson G, Hjartarson E, Sigurdsson A, Magnusdottir A, et al. Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nat Genet. 2016;48(6):634–9. https://doi.org/10.1038/ng.3561.CrossRefPubMed

66.

Dewey FE, Gusarova V, Dunbar RL, O’Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017; https://doi.org/10.1056/NEJMoa1612790.

67.

Do R, Stitziel NO, Won HH, Jorgensen AB, Duga S, Angelica Merlini P, et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2015;518(7537):102–6. https://doi.org/10.1038/nature13917. CrossRefPubMed

Title: ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen
Authors: Natalia A. Rocha
Cara East
Jun Zhang
Peter A. McCullough
Publication date: 01-12-2017
Publisher: Springer US
Published in: Current Atherosclerosis Reports / Issue 12/2017
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-017-0697-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 12/2017

Glycocalyx in Atherosclerosis-Relevant Endothelium Function and as a Therapeutic Target

Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: Beyond Vasospasm and Towards a Multifactorial Pathophysiology

Organic Ion Transporters and Statin Drug Interactions

The Emergence of “Simpler” Surgical Options to Treat Obesity and Metabolic Syndrome

The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis

Review of Cardiometabolic Effects of Prescription Omega-3 Fatty Acids

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page